by John Binder
Big pharmaceutical corporations are raking in billions from American taxpayers through the United States government deals that are funding research for a vaccine to the Chinese coronavirus.
In May, President Donald Trump’s administration created Operation Warp Speed (OWS) to partner with pharmaceutical corporations in researching, developing, and administering a vaccine for the coronavirus at a record pace.
As a result, the administration is cutting deals for pharmaceutical corporations that deliver them billions in taxpayer dollars for vaccine research and development.
Most recently, the France-based pharmaceutical corporation Sanofi and GSK scored a $2.1 billion federal contract for 100 million doses of a vaccine with potentially the option to buy another 500 million doses. Sanofi profits total nearly $38 billion.
Similarly, Pfizer and BioNTech won a $1.95 billion federal contract for an initial 100 million doses of their yet-to-be-developed vaccine for coronavirus. Pfizer is the largest multinational pharmaceutical corporation in the world with profits over $53 billion.
Other pharmaceutical corporations who have been awarded federal funds include:
- Nearly $1 billion to Moderna
- About $420 million to Johnson & Johnson
- $1 billion to AstraZeneca
- $1.6 billion to Novavax
- $450 million to Regeneron Pharmaceuticals
